PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient
(2022-07-27 | NDAQ:ATNF) 180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp.